Tradename | Company | Number | Date | Products |
---|---|---|---|---|
SILENOR | Currax Pharmaceuticals | N-022036 RX | 2010-03-17 | 2 products, RLD, RS |
ZONALON | Mylan | N-020126 RX | 1994-04-01 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
doxepin | ANDA | 2024-10-03 |
doxepin hcl | ANDA | 2024-10-16 |
doxepin hydrochloride | ANDA | 2024-10-10 |
prudoxin | New Drug Application | 2017-06-29 |
silenor | New Drug Application | 2023-05-08 |
zonalon | New Drug Application | 2017-06-14 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Doxepin Hydrochloride, Silenor, Currax | |||
8513299 | 2030-09-07 | U-620 | |
9532971 | 2029-06-01 | DP | |
9107898 | 2028-05-01 | U-620 | |
9907780 | 2028-04-11 | DP | |
10548871 | 2028-04-11 | U-620 | |
11096920 | 2028-04-11 | U-620 | |
11234954 | 2028-01-18 | U-620 | |
7915307 | 2027-08-24 | U-620 | |
9572814 | 2027-07-20 | U-620 | |
10653660 | 2027-07-20 | U-620 | |
11110074 | 2027-07-20 | U-620 | |
9486437 | 2027-05-18 | U-620 | |
9861607 | 2027-05-18 | U-620 | |
10238620 | 2027-05-18 | U-620 | |
10653662 | 2027-05-18 | U-620 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pruritus | D011537 | HP_0000989 | L29 | — | — | — | 1 | 3 | 4 |
Sleep initiation and maintenance disorders | D007319 | — | F51.01 | 1 | 1 | — | 1 | — | 3 |
Depression | D003863 | — | F33.9 | — | — | 1 | 1 | — | 2 |
Atrophy | D001284 | — | — | — | — | — | 1 | — | 1 |
Treatment-resistant depressive disorder | D061218 | — | — | — | — | — | 1 | — | 1 |
Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | — | 1 | — | 1 |
Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | — | 1 | — | 1 |
Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | 1 | — | 1 |
Ataxia | D001259 | — | R27.0 | — | — | — | 1 | — | 1 |
Healthy volunteers/patients | — | — | — | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Psychophysiologic disorders | D011602 | — | F45.9 | — | — | 1 | — | 1 | 2 |
Somatoform disorders | D013001 | — | F45 | — | — | 1 | — | 1 | 2 |
Stomatitis | D013280 | EFO_1001904 | K12.1 | — | — | 2 | — | — | 2 |
Mucositis | D052016 | EFO_1001898 | — | — | — | 2 | — | — | 2 |
Dementia | D003704 | EFO_0003862 | F03 | — | — | 1 | — | — | 1 |
Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 1 | — | — | 1 |
Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | — | 1 |
Head and neck neoplasms | D006258 | — | — | — | — | 1 | — | — | 1 |
Pain | D010146 | EFO_0003843 | R52 | — | — | 1 | — | — | 1 |
Urticaria | D014581 | EFO_0005531 | L50 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Carcinoma | D002277 | — | C80.0 | — | 1 | — | — | 1 | 2 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
Dermatitis | D003872 | HP_0011123 | L30.9 | — | 1 | — | — | — | 1 |
Radiodermatitis | D011855 | — | L58 | — | 1 | — | — | — | 1 |
Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | — | 1 |
Thyroid neoplasms | D013964 | EFO_0003841 | — | — | 1 | — | — | — | 1 |
Esophageal neoplasms | D004938 | — | C15 | — | 1 | — | — | — | 1 |
Lung neoplasms | D008175 | HP_0100526 | C34.90 | — | 1 | — | — | — | 1 |
Sarcoma | D012509 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 2 | 2 |
Drug interactions | D004347 | — | — | — | — | — | — | 1 | 1 |
Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | — | 1 | 1 |
Gastrointestinal diseases | D005767 | — | — | — | — | — | — | 1 | 1 |
Dyspepsia | D004415 | EFO_0008533 | K30 | — | — | — | — | 1 | 1 |
Digestive system diseases | D004066 | HP_0011024 | K92.9 | — | — | — | — | 1 | 1 |
Nasopharyngeal carcinoma | D000077274 | — | — | — | — | — | — | 1 | 1 |
Breakthrough pain | D059390 | — | — | — | — | — | — | 1 | 1 |
Drug common name | Doxepin |
INN | doxepin |
Description | Doxepin is a medication belonging to the tricyclic antidepressant (TCA) class of drugs used to treat major depressive disorder, anxiety disorders, chronic hives, and insomnia. For hives it is a less preferred alternative to antihistamines. It has a mild to moderate benefit for sleeping problems. It is used as a cream for itchiness due to atopic dermatitis or lichen simplex chronicus.
|
Classification | Small molecule |
Drug class | tricyclic compounds |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CN(C)CCC=C1c2ccccc2COc2ccccc21 |
PDB | — |
CAS-ID | 1668-19-5 |
RxCUI | — |
ChEMBL ID | CHEMBL1628227 |
ChEBI ID | 4710 |
PubChem CID | 3158 |
DrugBank | DB01142 |
UNII ID | 5ASJ6HUZ7D (ChemIDplus, GSRS) |